Oncology (sarcoma, H&N, CUP). EBM, Health Policy @HUG_ge (Geneva), @vkprasadlab (UCSF). Geneva Ethics Committee. Co-EiC ESMO Rare Cancers. No COI. Views mine.
Genève, Suisse
- Tweets 2,602
- Following 421
- Followers 3,005
- Likes 3,591
Timothée Olivier, MD retweeted
Ben, sorry but I disagree: 42% ORR comes from a selected n=38 subgroup pooled across 160–220 mg, while ORR in the overall 160–220 mg population was 34%. Encouraging activity, for sure, but safety matters too. I’d be cautious about advocating for EAP based on such a small selected subgroup.
3
2
12
1,054
Timothée Olivier, MD retweeted
This is CRAZY. The test didn’t meet its endpoint and the study was not designed to assess harm and showed no benefit.
reuters.com/business/healthc…
13
10
59
7,262
Timothée Olivier, MD retweeted
Multicancer early detection tests
What we know/ What we don't
Access vs Payment
9
13
101
22,879
GRAIL’s Galleri is being reviewed by an FDA advisory committee on September 23. $GRAL @FDA
This paper co-authored with @VPrasadMDMPH and @AlysonHaslam couldn't be more timely... 👇
4
14
3,830
Timothée Olivier, MD retweeted
Are Blood-Based Cancer Screening Tests Ready for Primetime?
amjmed.com/action/showPdf?pi…
6
8
48
12,705
"Statistics in Oncology in Practice", fom my talk available at theoncologyshot.com/p/my-fri…
A change in sample size should always be transparently explained.
If not, there is a risk of what we call "p-hacking", "data-dredging"
See here with an example with the PANOVA trial👇
2
8
45
2,359
"Statistics in Oncology in Practice", my new talk is available at theoncologyshot.com/p/my-fri…
Here is an excerpt: understanding the principles of Kaplan-Meier is fundamental, a practical example with LUNAR @Alfdoc2 !
2
42
187
13,781
Timothée Olivier, MD retweeted
High praise from @VPrasadMDMPH
"Venk Murthy— a smart man— joins the team"
"Venk is a great pick"
🙏 👍
open.substack.com/pub/vinayp…
3
4
66
8,808
Timothée Olivier, MD retweeted
Had an amazing time with colleagues in 🇮🇳 at the Mumbai Hematology Meeting. Inspired by how hematologists there are striving to achieve the best outcomes for their patients despite drug access and cost barriers. In myeloma/amyloidosis context, themes that repeatedly came up were time-limited BsAb therapies, reducing cost, and preventing/managing infections!
@Aditya_PGI @mishrak20 @nikhil91sjmc
#mmsm
2
9
44
1,866
Timothée Olivier, MD retweeted
ESMO Sarcoma and Rare Cancers 2027: Your findings today could shape tomo... piped.video/tCCvblSuE6U?si=ADKI… via @YouTube
5
20
3,785
Timothée Olivier, MD retweeted
Respectfully I agree with the principle of AA, but I’m not sure “everyone benefits” equally. The asymmetry is striking: patients and payers take the clinical uncertainty, while pharma gets full pricing from day one. If a drug enters the market on phase I/II data at $30–40K/month and the phase III turns negative years later, that is hardly a balanced bet. Perhaps AA should come with accelerated pricing too , with price escalation only once clinical benefit is confirmed? @Timothee_MD
1
4
20
2,264
Timothée Olivier, MD retweeted
10 reasons we don' t have more cancer cures
Beyond the NYTimes
14
9
106
24,789
A Cultural Gap: How Many Patients With Metastatic Pancreatic Cancer Do Not Start Systemic Therapy?
Different cultural approches between the Netherlands and the US via @Timothee_MD
theoncologyshot.com/p/a-cult…
1
2
7
1,045
"A Cultural Gap: How Many Patients With Metastatic Pancreatic Cancer Do Not Start Systemic Therapy?"
I was striked by the difference in the proportion of patients NOT receiving systemic therapy for pancreatic cancer:
- US=33%...
- Netherlands=72% ‼️
👉 theoncologyshot.com/
1
3
17
1,511
“Chemo‑free” is not always better: the @FDA withdrawal of adagrasib in colorectal cancer via #SaharBarjestehvanWaalwijkvanDoornKhosrovani
theoncologyshot.com/p/chemof… @DrMarkLythgoe
6
15
1,574
Timothée Olivier, MD retweeted
No secret. Been going on for 40 years +
This is infuriating.
Big Pharma is secretly “ghostwriting” articles in top medical and oncology journals to trick doctors into buying their drugs.
Here’s how the scam works:
They bankroll specialized medical-writing firms to ghostwrite studies that look rigorous and independent.
Next, they recruit well-known physicians and academics, dangling prestige, speaking fees, and career advancement in exchange for simply putting their names on the finished product.
Once these ghostwritten articles appear in elite journals, everyday doctors read them as gospel. They prescribe accordingly, convinced the data is real.
The result? Billions in extra drug sales… while patients are exposed to treatments whose risks and benefits have been carefully engineered on paper.
Dr. Russell Blaylock explains how the “conspiracy theorists” weren’t theorizing — they were documenting an industrial-scale deception.
1
8
30
3,203
Timothée Olivier, MD retweeted
Our paper is just out in @JCO_ASCO !
W/ @SruthiRanganat1, open-access !
"Daraxonrasib in Pancreatic Cancer: From Second-Line Breakthrough to First-Line Evidence"
Even more relevant after the recent @FDA approval, with a label going beyond the data.
ascopubs.org/doi/10.1200/JCO…
a thread🧵1/👇
3
15
55
5,292
Adagrasib was just withdrawn by the @FDA in metastatic colorectal cancer based on the negative results in KRYSTAL-10
"A waterfall plot can look impressive, and high response rates can create enthusiasm, but they should not be confused with proven clinical benefit."
From Sahar van Waalwijk, new guest post in
theoncologyshot.com !
2
37
94
65,496
Our paper is just out in @JCO_ASCO !
W/ @SruthiRanganat1, open-access !
"Daraxonrasib in Pancreatic Cancer: From Second-Line Breakthrough to First-Line Evidence"
Even more relevant after the recent @FDA approval, with a label going beyond the data.
ascopubs.org/doi/10.1200/JCO…
a thread🧵1/👇
3
15
55
5,292
What we did not cover in our article, because it was recently annouced together with the FDA approval, is the huge cost of the drug, recently set at 39 800 $ per month in the US!💲‼️
Financial toxicity is real and damaging for patients.
16/
1
190
Concluding words:
- there is no doubt daraxonrasib is an advance, however standing ovations and celebrations may give the public the false impression a cure was found. This is unfortunately not true. Whether this drug will translate in more cure in earlier settings has to be proven.
- beside the efficacy results, significant toxicities, including financial, has to be considered. While chemotherapy is also significantly toxic, it allows treatment-free periods which is not the case with daraxonrasib.
- maintaining nuances is also needed to permit the generation of futher evidence, like here allowing the first-line RASolute 303 trial to be appropriately conducted
- still, key amendements are needed : RASolute 303 should incorporate a mandatory daraxonrasib cross-over (if not already), and modify the third, chemotherapy-only control arm, into a real "phyisician's choice" chemotherapy arm, including triplet chemotherapies which are routinely used in the real-life.
Looking forward to what you think, thanks to my co-author @SruthiRanganat1!
Thanks for following 🙏
Full article here:
ascopubs.org/doi/10.1200/JCO…
17/17
Daraxonrasib in Pancreatic Cancer: From Second-Line Breakthrough to First-Line Evidence
ascopubs.org 1
1
256